Landogrozumab - CISMeF

Preferred Label : Landogrozumab;

NCIt synonyms : Anti-myostatin Monoclonal Antibody LY2495655;

NCIt definition : A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration, landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.;

UNII : B1792M902R;

CAS number : 1391726-30-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1391726-30-9 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : LY2495655;

Details

Origin ID

C99640;

UMLS CUI

C4519737;

Automatic exact mappings (from CISMeF team)
- landogrozumab [MeSH concept]
Currated CISMeF NLP mapping
- landogrozumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- landogrozumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Growth/Differentiation Factor 8 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients